1. Location:
2. Home
3. NEWS
4. The details information

The consistency evaluation of Tirofiban Hydrochloride and Sodium Chloride Injection from Xi’an Wanlong Pharmaceutical was approved

On April 14, 2022, the Product Xintuo® (Tirofiban Hydrochloride and Sodium Chloride Injection) 100ml: 5mg consistency evaluation application was approved by the National Medical Products Administration, it is the second approved product of consistency evaluation for Xi’an Wanlong.

Tirofiban Hydrochloride and Sodium Chloride Injection is an antithrombotic drug for cardiovascular and cerebrovascular diseases. Its characteristics of rapid, powerful and safe anti-platelet aggregation have been recognized by clinicians, and is also recommended by a number of clinical guidelines and experts at home and abroad.

Our company always regards quality and safety as the primary task of the enterprise, and at the same time, fully implements the pharmaceutical consistency evaluation work of the "12th Five-Year Plan of National Medical Safety". In April 2021, our company submitted the consistency evaluation application of "Tirofiban Hydrochloride and Sodium Chloride Injection" to Center for Drug Evaluation, NMPA (registration number: CYHB2150538), and was successfully approved on April 14, 2022.

Our company insist on developing and manufacturing first-class products, earnestly fulfill the duties of pharmaceutical industry, and actively contribute to the society. The successful evaluation of Tirofiban Hydrochloride and Sodium Chloride Injection is also the embodiment of enterprise spirit. Xi'an Wanlong Pharmaceutical will continue to increase the investment in scientific and technological innovation, continuous development and innovation, to provide patients with reliable quality, significant curative effect, safe and secure good medicine, and continue to serve the society with high-quality products!